News Column

Transcatheter Technologies Receives Second Tranche of Series B Cash Infusion

June 16, 2014

By a News Reporter-Staff News Editor at Clinical Trials Week -- Transcatheter Technologies GmbH, an emerging medical device company that is developing a third-generation transcatheter aortic valve implantation (TAVI) system-Trinity (Click here for video) - announced the closing of the second tranche of a Series B financing. The company's founder and CEO, Wolfgang Goetz, M.D., Ph.D., will be looking to meet with additional investors, including potential corporate partners, at the Cardiovascular Research Foundation's "TVT 2014" meeting in Vancouver starting later this week (see also Transcatheter Technologies GmbH).

The company has previously announced successful 6-month follow-up results for a pilot study of its Trinity TAVI system that is designed to be the world's first 'truly repositionable' and, therefore, best TAVI system.

"The six-month clinical results are striking," said principal investigator Prof. Dr. Christian Hengstenberg. A cardiologist at the German Heart Center, Munich, Germany, Prof. Dr. Hengstenberg. "Unlike the second-generation TAVI systems, the Trinity aortic valve is able to be positioned precisely or in fact repositioned, even after full implantation, in a safe manner. In our study, Trinity's novel sealing cuff continues to provide outstanding results without PVL, which is an unacceptably frequent complication of TAVI(1). Equally important, the risk of atrio-ventricular (AV) block has been mitigated due to the supra-annular positioning of the Trinity valve."

Keywords for this news article include: Clinical Trials and Studies, Transcatheter Technologies GmbH.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Clinical Trials Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters